Combined PD-L1 and B7-H3 fusion protein vaccination (CK life)

PD-L1/B7-H3融合蛋白联合疫苗 (长江生命科技)

Report date: 2026/05/15 20:01:45

Base Information

Drug NameCombined PD-L1 and B7-H3 fusion protein vaccination (CK life)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccineBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionProgrammed death-ligand 1 blockersAnti-CD276
TargetsProgrammed death-ligand 1CD276 antigen
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHong Kong
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCk Life Sciences Int'L (Holdings) Inc
China Registration ClassN/A

Develop Information

Active CompaniesCk Life Sciences Int'L (Holdings) Inc
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A